TRex Bio, Inc. AI Stock Analysis
TRex Bio, Inc. (TRXB) AI Stock Analysis
TRex Bio, Inc.
(NASDAQ:TRXB)
No summary available
TRex Bio, Inc. (TRXB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $83.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 154.36K
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 1.04
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 60
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
TRex Bio, Inc. Business Overview & Revenue Model
Company Description
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil D...
TRex Bio, Inc. Peers Comparison
Overall Rating
KNSA80Outperform
CORT76Outperform
CTOR44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $7.47B | 66.08 | 17.27% | ― | 58.19% | 192.34% | |
| 76Outperform | $7.67B | 46.55 | 22.94% | ― | 30.02% | 48.80% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $50.92M | -1.20 | -102.97% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TRXB | TRex Bio, Inc. | 9.39 | -4.61 | -32.93% | |
| CORT | Corcept Therapeutics | 67.79 | -7.26 | -9.67% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. Class A | 95.05 | 53.56 | 129.09% | |
| CTOR | Citius Oncology, Inc. | 0.56 | -0.57 | -50.71% | |
| CUVL | Clinuvel Pharmaceuticals Limited Sponsored ADR | 4.86 | -2.19 | -31.11% | |
| ETRA | Electra Therapeutics Inc. | 8.43 | -4.82 | -36.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
